Anorexia

Circulating lipocalin-2 is associated with systemic inflammation and cachexia-related features in patients with gastrointestinal cancer.

BACKGROUND

Cancer-associated anorexia (AN) and cachexia are frequent and debilitating complications of cancer, driven by systemic inflammation and metabolic dysregulation. Lipocalin 2 (LCN2) has been implicated in immune-metabolic integration and central appetite control, however data in cancer patients are limited. This...

🗓️ 2026-11-03
📰 Publication: Frontiers In Nutrition
Read MoreCirculating lipocalin-2 is associated with systemic inflammation and cachexia-related features in patients with gastrointestinal cancer.

Pre-clinical cancer cachexia causes glucose hypermetabolism prior to overt weight loss.

PURPOSE

Cancer cachexia is a life-threatening complication of advanced malignancies, driven by profound systemic metabolic reprogramming and anorexia. Insulin action is markedly impaired in patients with cancer and may contribute directly to cachexia pathogenesis. However, the interplay between weight loss, food...

🗓️ 2026-07-18
📰 Publication: Molecular Metabolism
Read MorePre-clinical cancer cachexia causes glucose hypermetabolism prior to overt weight loss.

Cancer cachexia: A tumor-driven disorder of whole-body homeostasis.

Cancer cachexia is a systemic metabolic syndrome driven by tumor-induced disruption of whole-body homeostasis. Characterized by skeletal muscle atrophy and adipose tissue loss, cachexia leads to functional decline, impaired quality of life, reduced treatment tolerance, and poor survival across multiple...

🗓️ 2026-04-18
📰 Publication: Cancer Cell
Read MoreCancer cachexia: A tumor-driven disorder of whole-body homeostasis.

Phenotype profiling of disease-related malnutrition with inflammation: Document elaborated by the ESPEN special interest group (SIG) ''cachexia-anorexia in chronic wasting diseases''.

In the ESPEN SIG meetings the similarities and differences between cachexia and disease-related malnutrition (DRM) were previously analyzed, as well as the role of inflammation in DRM. In the years 2023-2025, the SIG moving forward emphasized the relevance of the...

🗓️ 2026-02-24
📰 Publication: Clinical Nutrition
Read MorePhenotype profiling of disease-related malnutrition with inflammation: Document elaborated by the ESPEN special interest group (SIG) ''cachexia-anorexia in chronic wasting diseases''.

Nutrition Rehabilitation Programs and Cachexia Clinics for Anorexia-Cachexia Syndrome in Patients with Cancer.

The Anorexia-Cachexia Syndrome (ACS) is characterized by loss of appetite and unintentional weight loss. Important clinical outcomes are associated with ACS including increased risk of chemotherapy side-effects, decreased survival and quality of life. Because ACS is driven by complex metabolic...

🗓️ 2026-02-16
📰 Publication: Oncologist
Read MoreNutrition Rehabilitation Programs and Cachexia Clinics for Anorexia-Cachexia Syndrome in Patients with Cancer.

Quality of Life of Colorectal Cancer Patients Treated with Chemotherapy.

Background/Objectives: Colorectal cancer (CRC) is associated with anorexia-cachexia syndrome, which negatively affects health-related quality of life (HRQoL). This study aimed to evaluate HRQoL and functional status in CRC patients undergoing chemotherapy who were eligible for oral nutritional supplementation (ONS). Methods:...

🗓️ 2026-01-28
Read MoreQuality of Life of Colorectal Cancer Patients Treated with Chemotherapy.

New models for cancer cachexia and their application to drug discovery.

Cancer cachexia (CC) is a multifactorial syndrome characterized by progressive weight loss, anorexia, and loss of skeletal muscle and fat mass, resulting in reduced quality of life and poor prognosis. Currently, there are no approved pharmacological treatments for CC, highlighting...

🗓️ 2025-10-03
📰 Publication: Expert Opinion On Drug Discovery
Read MoreNew models for cancer cachexia and their application to drug discovery.

Assessing the need for multimodal care in anorexia and cachexia patients with advanced cancer referred to palliative care: a secondary analysis of a multicenter survey in Japan.

There are no methods for assessing the need for multimodal care in cancer cachexia. We examined nine components in evaluating needs among advanced cancer patients. This was a self-administered survey. Participants rated their nutrition impact symptoms (NISs) using a numerical...

🗓️ 2025-09-06
📰 Publication: Supportive Care In Cancer
Read MoreAssessing the need for multimodal care in anorexia and cachexia patients with advanced cancer referred to palliative care: a secondary analysis of a multicenter survey in Japan.

Olanzapine for Anorexia in Patients With Incurable Cancer and Cachexia (OlAnCa): A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.

Pharmacologic options for managing anorexia in cancer cachexia are limited. This trial aimed to evaluate the efficacy of olanzapine in alleviating anorexia in patients with incurable cancer and cachexia. This double-blind, placebo-controlled, randomized trial included adult patients with incurable cancer...

🗓️ 2025-07-30
📰 Publication: Journal Of The National Comprehensive Cancer Network
Read MoreOlanzapine for Anorexia in Patients With Incurable Cancer and Cachexia (OlAnCa): A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.

Anti-CGRP Monoclonal Antibodies Counteract Establishment of Food Aversive Memories and Chemotherapy-induced Anorexia and Weight Loss.

Glutamatergic neurons of external lateral parabrachial nucleus co-expressing calcitonin gene related peptide (elPB CGRP) negatively regulate food intake and establish food aversive memories. They also promote malaise-dependent anorexia, sickness behavior and tumor cachexia. In spite of the pathogenetic potential of...

🗓️ 2025-06-07
📰 Publication: Pharmacological Research
Read MoreAnti-CGRP Monoclonal Antibodies Counteract Establishment of Food Aversive Memories and Chemotherapy-induced Anorexia and Weight Loss.

Mechanisms and pharmacotherapy of cancer cachexia-associated anorexia.

Cachexia is a multifactorial metabolic syndrome characterized by weight and skeletal muscle loss caused by underlying illnesses such as cancer, heart failure, and renal failure. Inflammation, insulin resistance, increased muscle protein degradation, decreased food intake, and anorexia are the primary...

🗓️ 2025-02-01
📰 Publication: Pharmacology Research & Perspectives
Read MoreMechanisms and pharmacotherapy of cancer cachexia-associated anorexia.

Growth Differentiation Factor-15 Is Associated With Congestion-Related Anorexia and Weight Loss in Advanced Heart Failure.

Growth differentiation factor (GDF)-15 is a pleiotropic cytokine that is associated with appetite-suppressing effects and weight loss in patients with malignancy. This study aims to investigate the relationships between GDF-15 levels, anorexia, cachexia, and clinical outcomes in patients with advanced...

🗓️ 2025-01-08
📰 Publication: Jacc-Heart Failure
Read MoreGrowth Differentiation Factor-15 Is Associated With Congestion-Related Anorexia and Weight Loss in Advanced Heart Failure.

Prognostic Impact and Prevalence of Cachexia in Patients With Heart Failure: A Systematic Review and Meta-Analysis.

Cachexia, defined as the combination of weight loss, weakness, fatigue, anorexia and abnormal biochemical markers based on Evans' criteria, is known to exacerbate the prognosis of heart failure (HF) patients. This systematic review and meta-analysis investigates the prognostic impact and...

🗓️ 2024-10-30
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MorePrognostic Impact and Prevalence of Cachexia in Patients With Heart Failure: A Systematic Review and Meta-Analysis.

Impact of Cachexia and First-Line Systemic Therapy for Previously Untreated Advanced Non-Small Cell Lung Cancer: NEJ050A.

Cancer cachexia complicates advanced non-small cell lung cancer (NSCLC); however, it remains unclear how often cachexia occurs and how it affects the course of chemotherapy in patients receiving first-line systemic therapy. We conducted a multicentre, prospective observational study and enrolled...

🗓️ 2024-10-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreImpact of Cachexia and First-Line Systemic Therapy for Previously Untreated Advanced Non-Small Cell Lung Cancer: NEJ050A.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!